SER - Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinso

- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in accordance with the study protocol - - Company expects to provide a further update following completion of the Safety Monitoring Committee review – HUNTSVILLE, Ala., July 23, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE: SER ), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the completion of enrollment and dosing in Cohort 1 of its ongoing Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson’s disease. All eight patients in Cohort 1 have now been dosed across clinical sites in the United States and Australia. The milestone was achieved ahead of the Company’s previously disclosed guidance to complete Cohort 1 enrollment and dosing by the end of the third quarter of 2026.